microRNA-208a 在急性心肌梗死中的诊断和预后意义。
Diagnostic and Prognostic Significance of microRNA-208a in Acute Myocardial Infarction.
机构信息
Department of Cardiology, Affiliated Nanping First Hospital, Fujian Medical University, Nanping 353000, China.
Xiamen Anxinya Biological Technology Co. Ltd., Xiamen, Fujian 361005, China.
出版信息
Dis Markers. 2022 May 14;2022:7030722. doi: 10.1155/2022/7030722. eCollection 2022.
OBJECTIVE
To determine the prognostic and diagnostic significance of microRNA-208a (miR-208a) in acute myocardial infarction (AMI).
METHODS
Totally, 84 AMI patients hospitalized in our hospital between Jan. 2019 and Feb. 2021 were enrolled as the patient group (Pat group), and 50 healthy individuals over same time span as the control group (Con group). qRT-PCR assay was carried out to quantify serum miR-208a in the patients and receiver-operating characteristic (ROC) curves for analysing its diagnostic value in AMI patients and its predictive value in clinical efficacy and adverse events in the patients after therapy. The changes of miR-208a and clinical indexes ((lactate dehydrogenase (LDH), creatine kinase (CK) as well as Creatine kinase-MB (CK-MB)) in the patients before and after therapy were evaluated. Pearson's test was adopted to analyse the associations of miR-208a with clinical indexes. Additionally, the target genes of miR-208a were forecasted.
RESULTS
The patient group showed a higher miR-208a level than the control group ( < 0.05), and the area under the curve (AUC) of miR-208a in diagnosing AMI was >0.9. After therapy, patients presented notable decreases in serum miR-208a, LDH, CK, and CK-MB (all < 0.05). Serum miR-208a presented positive associations with LDH, CK, as well as CK-MB both before and after therapy (all < 0.05). Before therapy, the ineffective group presented a higher miR-208a level than the effective group ( < 0.05), and miR-208a had an AUC of 0.784 in forecasting efficacy. Additionally, the group with adverse events presented a higher miR-208a level than the group without them before therapy ( < 0.05), and miR-208a had an AUC of 0.713 in forecasting adverse events. According to enrichment analysis, the target genes of miR-208a were bound up with signal pathways of cellular senescence, MTOR and Wnt.
CONCLUSION
With high expression in AMI cases, miR-208a is a promising potential biomarker for diagnosis and prognosis forecasting of AMI.
目的
确定 microRNA-208a（miR-208a）在急性心肌梗死（AMI）中的预后和诊断意义。
方法
选取 2019 年 1 月至 2021 年 2 月在我院住院的 84 例 AMI 患者为患者组（Pat 组），同期 50 例健康个体为对照组（Con 组）。采用 qRT-PCR 法检测患者血清 miR-208a，分析其对 AMI 患者的诊断价值，以及对患者治疗后临床疗效和不良事件的预测价值。评估患者治疗前后 miR-208a 及临床指标（乳酸脱氢酶（LDH）、肌酸激酶（CK）和肌酸激酶同工酶-MB（CK-MB））的变化。采用 Pearson 检验分析 miR-208a 与临床指标的相关性。此外，预测 miR-208a 的靶基因。
结果
患者组 miR-208a 水平高于对照组（<0.05），miR-208a 诊断 AMI 的曲线下面积（AUC）>0.9。治疗后，患者血清 miR-208a、LDH、CK 和 CK-MB 均显著下降（均<0.05）。血清 miR-208a 与治疗前后的 LDH、CK 和 CK-MB 呈正相关（均<0.05）。治疗前，无效组 miR-208a 水平高于有效组（<0.05），miR-208a 预测疗效的 AUC 为 0.784。此外，治疗前发生不良事件组的 miR-208a 水平高于未发生不良事件组（<0.05），miR-208a 预测不良事件的 AUC 为 0.713。根据富集分析，miR-208a 的靶基因与细胞衰老、MTOR 和 Wnt 信号通路有关。
结论
miR-208a 在 AMI 病例中高表达，是 AMI 诊断和预后预测的有潜力的生物标志物。
Zotero 插件